Thank you so much for having me. My name is Jeff Sharman. I work at the Willamette Valley Cancer Institute and Research Center in Eugene, Oregon. And I'm the medical director of hematology research for the Sarah Cannon Research Institute. I had the opportunity to present the Phase II Morning Sun study. This was a basket study that looked at a variety of different cohorts of individuals. What I was reporting out was the safety and efficacy of mosinotuzumab in an elderly population with diffuse large B-cell lymphoma who are ineligible for standard R-mini-chop chemotherapy. Mosinotuzumab is a CD3 by CD20 bispecific antibody. It's approved for patients with relapsed follicular lymphoma. And because follicular lymphoma and diffuse large B-cell lymphoma share a lot of similarities, we wanted to see how this drug would behave in that setting. Patients above age 80 oftentimes don't tolerate the standard therapy very well. In fact, they can really struggle with it. And although there's a standard with R-mini-chop, it's a standard that I think a lot of investigators want to get rid of because it's hard to administer. So we allowed patients age 80 and above, or if patients were 65 and above and they didn't have adequate functional status to receive chemotherapy, those were eligible too. The treatment was single agent, no chemotherapy. This was entirely immunotherapy. And it was administered on days 1, 8, and 15 of the first three-week cycle. And then after that, it was just once every three weeks. Since this is just purely immunotherapy and we were getting rid of chemotherapy altogether, we wanted to see how it would do. What we saw was that about 70% of patients had a response, 50% of patients had a complete response. And for those patients who had a complete response, many of them we couldn't even find small traces of their disease. What we call measurable residual disease was negative in those patients. And if they got a measurable residual disease negative test and had a CR, none of those patients relapsed during the period of time. Now we only looked for about 12 and a half months. We're going to continue to follow, see how these patients do over time. The other really exciting thing about this was how well patients tolerated. This was not chemotherapy. And so one of the common side effects of this class of medications is what we call cytokine release syndrome. It's like an inflammatory syndrome where the body's inflammation takes over. And we saw that in very few patients, 12% of patients. And most of it was very low grade, meaning it didn't result in much in the way of complications. So altogether we saw what appears to be a pretty safe therapy to administer. It looked to be very effective. It is not yet the standard of care, but that's really the next steps of our research is to figure out how do we create a clinical trial where we could potentially replace our mini chop in this population. So that's what we're going to be working on next. If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference. And we're deeply grateful for your support.
HealthTree • December 22, 2025